Bioinformatics analysis reveals the ceRNA co-expression network in tumor microenvironment and prognostic biomarkers in Sarcomas

Dandan Zou (✉ zodan101@126.com)  
Department of Radiology, The First Hospital of Qinhuangdao

Yang Wang  
Department of MRI, The Third Hospital of Qinhuangdao

Meng Wang  
Department of Clinical Laboratory, The First Hospital of Qinhuangdao

Bo Zhao  
Department of Radiology, The First Hospital of Qinhuangdao

Fei Hu  
Department of Radiology, The First Hospital of Qinhuangdao

Yanguo Li  
Department of Radiology, The First Hospital of Qinhuangdao

Bingming Zhang  
Department of Radiology, The First Hospital of Qinhuangdao

Research

Keywords: Sarcomas, tumor microenvironment, prognosis, mRNA, miRNA, IncRNA, ceRNA

DOI: https://doi.org/10.21203/rs.3.rs-36486/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

Sarcomas (SARCs) are rare, heterogeneous mesenchymal neoplasia. To understand the tumor microenvironment (TME) and identify potential biomarkers for prognosis that associated with TME of SARCs might provide effective clues for immune therapy.

Methods

We evaluated the immune scores and stromal scores by using the RNA sequencing dataset of SARCs patients from The Cancer Genome Atlas (TCGA) database and the ESTIMATE algorithm. Then the differentially expressed mRNAs (DEGs), miRNAs (DEM) and IncRNAs (DELs) were filtered after comparing the two high- and low- scores groups. Next, based on these DERNAs, we established a competing endogenous RNA (ceRNA) network and explored the prognostic roles of biomarkers involved in the network with the help of bioinformatics analysis.

Results

High immune scores were significantly associated with favorable overall survival of SARCs patients. Next, a total of 328 DEGs, 18 DEMs and 67 DELs that commonly regulated in the immune and stromal scores groups were obtained. And for the DEGs, some of the Gene Ontology (GO) terms and pathways were mainly associated with immune processes. A ceRNA network were constructed with 142 nodes and 424 edges, in which hsa-miR-9-5p, hsa-miR-490-3p, hsa-miR-133a-3p, hsa-miR-133b and hsa-miR-129-5p were the top 5 nodes. Additionally, the protein-protein Interaction (PPI) network identified MMP9, TYROBP, CSF1, CXCR4, FBN1, FLNA, PDGFRB, CYBB, FCGR3A and MYH11 as hub nodes with considerable importance that functioned in the network. Finally, the Kaplan-Meier survival analysis demonstrated that 9 mRNAs (APOL1, EFEMP1, LYZ, MEDAG, MYH11, RARRES1, TNFAIP2, TNFSF10 and ZNF385A), 2 miRNAs (hsa-miR-9-5p and hsa-miR-183-5p) and 3 lncRNAs (CTD-2228K2.7, HOTAIRM1 and NCF1C) were closely associated with the overall survival of SARCs patients.

Conclusions

Taken together, our study confirmed that the prognosis value of immune scores for SARCs patients, also we identified a list of TME-related biomarkers which might contribute to prognostic prediction and help improve the efficacy of immune therapy.

Introduction
Sarcomas (SARCs) are rare, heterogeneous mesenchymal neoplasia and typically divided into two groups (bone SARCs and soft tissue SARCs) [1]. In the US, there were about 10,700 SARC diagnoses and 3,800 deaths per year, while in Europe, SARCs accounts for only 1–2% of all cancers in adults with an overall annual incidence of 5.6 cases per 100,000 adults [2, 3]. At present, clinical treatments including surgical resection, radiotherapy and chemotherapy which were adopted singly or together could be effective ways in treating SARCs. However, more than half SARCs patients suffered with a high-risk of metastasis and death for the blood transfer of SARCs in early stages [4].

Recent elucidation of the relationships between cancer cells and immune systems has contributed to the development of immunotherapy [5]. One of the most successful strategies involve immune checkpoint inhibitors, for example, PD-1 (programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expressions were signicantly correlated with CD8 + tumor infiltrating lymphocytes [6]. And their expression were also associated with clinical stage, distant metastasis, poor differentiation of tumor, overall survival and event-free survival in SARCs patients [7]. Thus, understanding the tumor microenviroment (TME) and identifying potential biomarkers that associated with TME of SARCs is critical to improve the efficacy of immune therapy.

TME is consisted of two essential components (infiltrating immune and stromal cells) that impact cancer prognosis [8]. And the emergence of Estimation of STromal and Immune cells in Malignant Tumours using Expression data (ESTIMATE) algorithm makes it possible to predict the infiltration of stromal and immune cells in tumors by generating stromal and immune scores based on Gene Set Enrichment Analysis of each tumor samples [9]. Recently, the ESTIMATE has been applied in several cancers, such as head and neck squamous cell carcinoma [10], glioblastoma [11] and acute myeloid leukemia [12]. A previous study used ESTIMATE algorithm to reveal the immune-related gene signature in bone SARCs [13], however, whether this algorithm could be used to investigate prognostic biomarkers in SARCs remains to be elucidated.

In this study, by using 262 SARCs tumor samples from The Cancer Genome Atlas (TCGA) database and the ESTIMATE algorithm, we aimed to establish a competing endogenous RNA (ceRNA) network and identify a set of TME-related biomarkers that are associated with survival in SARCs patients.

**Materials And Methods**

**Data processing and immune and stromal scores determination**

The RNA expression data and the basic clinical information downloaded from the TCGA database consists of 261 SARCs tumor samples (https://gdc.nci.nih.gov/). The immune and stromal scores were evaluated by applying the ESTIMATE algorithm using the estimate R package (R version 3.5.3) [9]. The clinical data of SARCs patients was shown in (Table S1). The scores were used to reflect the level of immune cell and stromal cells infiltration of tumor tissue.
DEGs, DEMs and DELs obtained based on immune and stromal scores

According to the median of immune and stromal scores, these SARCs samples were categorized into high- and low-score groups. $P < 0.05$, $|\text{Fold change (FC)}| > 1.5$ and $\text{FDR} < 0.05$ were set as cutoff criteria to filter for DEGs, DEMs and DELs of these two comparisons. Then, intersect DERNAs of immune and stromal scores groups showed with the Veen diagrams were selected for further analysis.

GO and KEGG analysis of DEGs

Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses of the intersection DEGs obtained above were performed with DAVID version 6.8 [14, 15]. GO terms including biological processes (BP), molecular functions (MF), and cellular components (CC) were evaluated. $P < 0.05$ represents significant difference.

Construction of the ceRNA and protein-protein Interaction (PPI) Network

Target genes of DEMs were predicted by utilizing Miranda (http://www.microrna.org/) and TargetScan (http://www.targetscan.org/), target IncRNAs of DEMs were predicted by utilizing MiRanda and PITA (https://genie.weizmann.ac.il/pubs/mir07/mir07_data.html). Then the common negatively regulated pairs of the MiRanda and TargetScan results, and MiRanda and PITA results, which were also differentially expressed were chosen for construction of the ceRNA network. In addition, for the DEGs in the ceRNA network, PPI network were performed to predict the interactions between them using STRING (https://string-db.org/). The networks were visualized by Cytoscape software (version 3.6.1).

Survival analysis

Based on the overall survival time of SARCs patients, Kaplan-Meier analysis was conducted to evaluate the prognostic effect of immune scores, stromal scores and all biomarkers regulated in the ceRNA network. A $P$ value less than 0.05 was considered as statistical significance.

Results

Immune scores are significantly associated with SARCs patients

RNA sequencing datasets of 261 patients with SARCs from the TCGA database were analyzed. With the ESTIMATE algorithm, we found that the immune scores for the patients ranged from $-1750.11$ to $3630.51$, and the stromal scores ranged from $-1384.46$ to $2518.94$ (Table S2).

Subsequently, in order to determine the relationship between immune and stromal scores and survival in SARCs samples, Kaplan-Meier survival analyses was performed. The results showed that SARCs patients...
with high immune scores had significantly longer overall survival time when compared with those with low immune scores ($P = 0.0283$; Fig. 1A). Meanwhile, SARCs patients with high stromal scores also had favorable outcomes than those with low stromal scores, though there was no statistical significance ($P = 0.293$; Fig. 1B).

**DEGs, DEMs and DELs obtained Based on immune and stromal scores**

In high immune scores vs. low immune scores group, 454 DEGs, 32 DEMs 106 DELs were identified. And in high stromal scores vs. low stromal scores group, 672 DEGs, 92 DEMs and 105 DELs were identified (Fig. 2A-2F). A total of 328 DEGs (258 upregulated and 70 downregulated), 18 DEMs (9 upregulated and 9 downregulated) and 67 DELs (50 upregulated and 17 downregulated) that commonly regulated in these two groups were obtained through Venn diagrams (Fig. 2G-2I).

**GO and KEGG analysis of DEGs**

328 commonly regulated DEGs above were used to explore their potential function. Top GO terms upregulated included neutrophil degranulation and innate immune response in BP; protein binding and serine-type endopeptidase activity in MF; extracellular exosome and extracellular region in CC. While the GO terms downregulated included muscle contraction and platelet aggregation in BP; protein binding and actin filament binding in MF; cytosol and cytoplasm in CC (Fig. 3A, 3B).

Additionally, for the KEGG pathways, the upregulated DEGs were significantly enriched in staphylococcus aureus infection, phagosome and tuberculosis, the downregulated DEGs were mainly involved in vascular smooth muscle contraction, focal adhesion and adrenergic signaling in cardiomyocytes (Fig. 3A, 3B). Furthermore, some of the GO terms and pathways were mainly associated with immune processes.

**Construction of ceRNA and PPI Network**

We firstly used the 18 common DEMs to predict mRNAs and IncRNAs using the algorithm mentioned above. 347 mRNAs and 260 IncRNAs that existed in both groups were predicted (Table S3, S4). After we compared these results of negatively regulated pairs predicted with the DEGs and DELs, 89 DEGs, 14 DEMs and 38 DELs were finally obtained to construct the ceRNA network. The network consisted of were constructed with 142 nodes and 424 edges, and the degrees of the top 5 nodes (hsa-miR-9-5p, hsa-miR-490-3p, hsa-miR-133a-3p, hsa-miR-133b and hsa-miR-129-5p) were 32, 27, 23, 22 and 17, respectively (Fig. 4A).

Then the PPI network which consisted of 67 nodes and 180 edges were conducted to show the interactions between DEGs in the ceRNA network. The top 10 genes (MMP9, TYROBP, CSF1, CXCR4, FBN1, FLNA, PDGFRB, CYBB, FCGR3A and MYH11) were considered as hub genes based on the degree of importance (Fig. 4B).

**Survival analysis**
We analyzed that association between 89 DEGs, 14 DEMs and 38 DELs in the ceRNA network and overall survival time of SARC patients. 9 mRNAs (APOL1, EFEMP1, LYZ, MEDAG, MYH11, RARRES1, TNFAIP2, TNFSF10 and ZNF385A) among 89 DEGs closely related to the overall survival of SARCs patients. And the high expression of all these 9 mRNAs were related to high survival rates in SARC patients. We also observed that the low expression of 2 miRNAs (hsa-miR-9-5p and hsa-miR-183-5p) among the 14 DEMs were related to favorable survival outcomes. In addition, 3 lncRNAs (CTD-2228K2.7, HOTAIRM1 and NCF1C) were closely associated with the overall survival of SARC patients. For CTD-2228K2.7 and HOTAIRM1, their low expressions were related to a high overall survival rate in SARC patients. While for NCF1C, its high expression was correlated with good survival time (Fig. 5).

Discussion

The current study was the first to investigate the ceRNA network that associated with TME of SARC based on TCGA database. We first used the ESTIMATE algorithm and found that SARC patients with high immune scores had longer overall survival time. This was similar to a previous study which reported the high immune scores has favorable outcomes in bone SARC patients [13]. While for the correlation between stromal scores and survival in SARC samples, we failed to find any significant difference.

Subsequently, this study filtered 328 DEGs, 18 DEMs and 67 DELs that commonly existed in both two high vs. low scores groups. Then the GO and pathway analysis showed that many of the DEGs mainly participate in immune processes. Next, we identified hsa-miR-9-5p, hsa-miR-490-3p, hsa-miR-133a-3p, hsa-miR-133b and hsa-miR-129-5p as the top 5 nodes in the ceRNA network, and MMP9, TYROBP, CSF1, CXCR4, FBN1, FLNA, PDGFRB, CYBB, FCGR3A and MYH11 were the top 10 genes in the PPI network, these results indicated that they might play more significant functions in the networks. Finally, we performed overall survival analysis of the 89 DEGs, 14 DEMs and 38 DELs in the ceRNA network and found that 9 mRNAs (APOL1, EFEMP1, LYZ, MEDAG, MYH11, RARRES1, TNFAIP2, TNFSF10 and ZNF385A), 2 miRNAs (hsa-miR-9-5p and hsa-miR-183-5p) and 3 IncRNAs (CTD-2228K2.7, HOTAIRM1 and NCF1C) were closely associated with the overall survival of SARC patients.

Expect for TNFSF10 (TRAIL), which has been reported in several subtypes of SARC, the rest prognostic biomarkers are novel for SARC. APOL1 is a novel BH3-only protein, and its overexpression could induce autophagy and autophagy-associated cell death in several kinds of cancer cells [16, 17]. It was overexpressed in pancreatic cancer, lung adenocarcinoma and papillary thyroid carcinomas compared to matched normal tissues, and their prognostic roles were found in pancreatic cancer and lung adenocarcinoma [18–20]. EFEMP1 can be found in different human tissues, is a member of the fibulin family of extracellular glycoproteins [21]. Its high expression helps enhance the tumor growth in pancreatic carcinoma cells via binding the EGF receptor and activate the MAPK and Akt pathways [22]. Also, EFEMP1 could promote the migration and invasion of bone SARC via MMP-2 with induction by AEG-1 via NF-κB signaling pathway, and EFEMP1 was also reported to be a poor prognostic indicator of bone SARC [23]. LYZ encodes human lysozyme and acts as a macrophage marker, its expression levels positively correlate with the numbers of CD68 + pSTAT1 + macrophages [24]. In addition, it could interact
with CD34+ cells and neutrophils that may predict an increased risk of thrombosis in essential thrombocythemia patients [25]. MEDAG was involved in the processes of lipid accumulation, adipocyte differentiation, and glucose uptake in mature adipocytes [26]. Overexpression of MEDAG was related to lymph node metastasis and poor prognosis in papillary thyroid microcarcinoma, which was also the first to report its roles in cancer [27]. MYH11, RARRES1 and TNFAIP2 have been commonly investigated in many cancers. MYH11 is a protein that participates in muscle contraction through the hydrolysis of adenosine triphosphate [28]. Its expression have been found to be associated with many kinds of cancer, such as lung cancer, bladder cancer [29], head and neck cancer [30] and colorectal cancer [31]. RARRES1 is also gene that dysregulated in several cancers. It could induce autophagy in prostate cancer and cervical cancer cells [32, 33]. A recent study confirmed that RARRES1 contributed to the regulation of dendritic cells, and acted as a novel immune-related biomarker for glioblastoma [34]. TNFAIP2 is abundant in immune cells like myelomonocytic cells, endothelial cells, peripheral blood monocytes, dendritic cells, intestinal M cell, and macrophages [35–37]. And it played essential roles in inflammation, cell proliferation, angiogenesis, migration, membrane nanotube formation [38]. ZNF385B belongs to the family of zinc-finger genes and encodes transcription factors. In serous ovarian cancer, the increased mRNA levels of ZNF385B contributed to shorter survival time of ovarian cancer patients [39].

For the 2 miRNAs (hsa-miR-9-5p and hsa-miR-183-5p) and 3 lncRNAs (CTD-2228K2.7, HOTAIRM1 and NCF1C), the expression of hsa-miR-9-5p could be downregulated by IncRNA TUG1, and TUG1 overturned the effect of miR-9-5p on the proliferation, colony formation, cell cycle arrest, and apoptosis in bone SARCs cells [40]. Hsa-miR-183-5p was the first found in SARCs, highly expressed hsa-miR-183-5p might be associated with a poor prognosis for Clear cell renal cell carcinoma patients [41]. In addition, it was also considered as the optimal diagnostic biomarkers for hepatocellular carcinoma [42]. The IncRNA HOTAIRM1 (HOXA transcript antisense RNA myeloid-specific 1) is a natural antisense transcript of HOXA1 gene and expresses in the myeloid lineage and induced during neuronal differentiation [43, 44]. The authors reported that HOTAIRM1/HOXA1 could downregulate the expression of suppressive molecules released by MDSCs and increase the antitumor immune response [45]. It has been reported to be involved in many malignant diseases [45–48], while it was the first to be found in SARCs. However, there is no study on the roles of CTD-2228K2.7 and NCF1C in TME of SARCs patients, which means that more investigations are needed.

**Conclusions**

Taken together, our study confirmed that the prognosis value of immune scores for SARCs patients, also we found that the following TME-related biomarkers (APOL1, EFEMP1, LYZ, MEDAG, MYH11, RARRES1, TNFAIP2, TNFSF10, ZNF385A, hsa-miR-9-5p, hsa-miR-183-5p, CTD-2228K2.7, HOTAIRM1 and NCF1C) might contribute to prognostic prediction and help improve the efficacy of immune therapy.

**Declarations**

**Authors’ contributions**
DZ and YW: conception and design of the research. MW and BZ: acquisition of data and analysis and interpretation of data. FH, YL and BZ: statistical analysis. DZ and YW: drafting the manuscript. FH, YL, BZ DZ and YW: revision of manuscript. All authors have read and approved the final manuscript.

Acknowledgements

None.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Availability of data and materials

The datasets of this article were generated from the TCGA database.

Funding

None.

Competing interests

The authors declare that there was no potential conflict of interest.

References

1. Jo VY, Doyle LA. Refinements in Sarcoma Classification in the Current 2013 World Health Organization Classification of Tumours of Soft Tissue and Bone. Surg Oncol Clin N Am. 2016;25:621–43.
2. Stiller CA, Trama A, Serraino D, Rossi S, Navarro C, Chirlaque MD, Casali PG. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer. 2013;49:684–95.

3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.

4. Cormier JN, Pollock RE. Soft tissue sarcomas. CA Cancer J Clin. 2004;54:94–109.

5. Miwa S, Nishida H, Tsuchiya H. Current status of immunotherapy for sarcomas. Immunotherapy. 2017;9:1331–8.

6. D’Angelo SP, Shoushtari AN, Agaram NP, Kuk D, Qin LX, Carvajal RD, Dickson MA, Gounder M, Keohan ML, Schwartz GK, Tap WD. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol. 2015;46:357–65.

7. Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S, Kim KM, Park HS, Lee H, Moon WS, Chung MJ, et al. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One. 2013;8:e82870.

8. Chen YP, Zhang Y, Lv JW, Li YQ, Wang YQ, He QM, Yang XJ, Sun Y, Mao YP, Yun JP, et al. Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications. Theranostics. 2017;7:3585–94.

9. Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.

10. Zhong Z, Hong M, Chen X, Xi Y, Xu Y, Kong D, Deng J, Li Y, Hu R, Sun C, Liang J. Transcriptome analysis reveals the link between lncRNA-mRNA co-expression network and tumor immune microenvironment and overall survival in head and neck squamous cell carcinoma. BMC Med Genomics. 2020;13:57.

11. Jia D, Li S, Li D, Xue H, Yang D, Liu Y. Mining TCGA database for genes of prognostic value in glioblastoma microenvironment. Aging. 2018;10:592–605.

12. Yan H, Qu J, Cao W, Liu Y, Zheng G, Zhang E, Cai Z. Identification of prognostic genes in the acute myeloid leukemia immune microenvironment based on TCGA data analysis. 2019, 68:1971–1978.

13. Hong W, Yuan H, Gu Y, Liu M, Ji Y, Huang Z, Yang J, Ma L. Immune-related prognosis biomarkers associated with osteosarcoma microenvironment. 2020, 20:83.

14. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44–57.

15. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37:1–13.

16. Wan G, Zhaoridgetu S, Liu Z, Kaini R, Jiang Z, Hu CA. Apolipoprotein L1, a novel Bcl-2 homology domain 3-only lipid-binding protein, induces autophagic cell death. J Biol Chem. 2008;283:21540–9.
17. Zhaorigetu S, Wan G, Kaini R, Jiang Z, Hu CA. ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death. Autophagy. 2008;4:1079–82.

18. Jian L, Yang G. Identification of Key Genes Involved in Diabetic Peripheral Neuropathy Progression and Associated with Pancreatic Cancer. 2020, 13:463–476.

19. Sharpnack MF, Chen B, Aran D, Kosti I, Sharpnack DD, Carbone DP, Mallick P, Huang K. Global Transcriptome Analysis of RNA Abundance Regulation by ADAR in Lung Adenocarcinoma. EBioMedicine. 2018;27:167–75.

20. Chidiac M, Fayyad-Kazan M, Daher J, Poelvoorde P, Bar I, Maenhaut C, Delrée P, Badran B, Vanhamme L. ApolipoproteinL1 is expressed in papillary thyroid carcinomas. Pathol Res Pract. 2016;212:631–5.

21. Timpl R, Sasaki T, Kostka G, Chu ML. Fibulins: a versatile family of extracellular matrix proteins. Nat Rev Mol Cell Biol. 2003;4:479–89.

22. Seeliger H, Camaj P, Ischenko I, Kleespies A, De Toni EN, Thieme SE, Blum H, Assmann G, Jauch KW, Bruns CJ. EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma. Mol Cancer Res. 2009;7:189–98.

23. Wang Z, Cao CJ, Huang LL, Ke ZF, Luo CJ, LinZW, Wang F, Zhang YQ, Wang LT. EFEMP1 promotes the migration and invasion of osteosarcoma via MMP-2 with induction by AEG-1 via NF-κB signaling pathway. Oncotarget. 2015;6:14191–208.

24. Sunakawa Y, Yang D, Cao S, Zhang W, Moran M, Astrow SH, Hsiang J, Stephens C, Tsuji A, Takahashi T, et al. Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2018;17:e741–9.

25. Guo C, Li Z. Bioinformatics Analysis of Key Genes and Pathways Associated with Thrombosis in Essential Thrombocythemia. Med Sci Monit. 2019;25:9262–71.

26. Yamamoto CM, Oakes ML, Murakami T, Muto MG, Berkowitz RS, Ng SW. Comparison of benign peritoneal fluid- and ovarian cancer ascites-derived extracellular vesicle RNA biomarkers. J Ovarian Res. 2018;11:20.

27. Song Y, Fu LJ, Li HT, Qiu XG. Evaluation of MEDAG gene expression in papillary thyroid microcarcinoma: associations with histological features, regional lymph node metastasis and prognosis. Sci Rep. 2019;9:5800.

28. Nie MJ, Pan XT, Tao HY, Xu MJ, Liu SL, Sun W, Wu J, Zou X. Clinical and prognostic significance of MYH11 in lung cancer. Oncol Lett. 2020;19:3899–906.

29. Hu J, Zhou L, Song Z, Xiong M, Zhang Y, Yang Y, Chen K, Chen Z. The identification of new biomarkers for bladder cancer: A study based on TCGA and GEO datasets. J Cell Physiol 2019.

30. Islam T, Rahman R, Gov E, Turanli B, Gulfidan G, Haque A, Arga KY. Haque Mollah N: Drug Targeting and Biomarkers in Head and Neck Cancers: Insights from Systems Biology Analyses. Omics. 2018;22:422–36.
31. Wang RJ, Wu P, Cai GX, Wang ZM, Xu Y, Peng JJ, Sheng WQ, Lu HF, Cai SJ. Down-regulated MYH11 expression correlates with poor prognosis in stage II and III colorectal cancer. Asian Pac J Cancer Prev. 2014;15:7223–8.

32. Roy A, Ramalinga M, Kim OJ, Chijioke J, Lynch S, Byers S, Kumar D. Multiple roles of RARRES1 in prostate cancer: Autophagy induction and angiogenesis inhibition. PLoS One. 2017;12:e0180344.

33. Shyu RY, Wang CH, Wu CC, Chen ML, Lee MC, Wang LK, Jiang SY, Tsai FM. Tazarotene-Induced Gene 1 Enhanced Cervical Cell Autophagy through Transmembrane Protein 192. Mol Cells. 2016;39:877–87.

34. Wang D, He MQ, Fan DQ. RARRES1 is a novel immune-related biomarker in GBM. Am J Transl Res. 2019;11:5655–63.

35. Sarma V, Wolf FW, Marks RM, Shows TB, Dixit VM. Cloning of a novel tumor necrosis factor-alpha-inducible primary response gene that is differentially expressed in development and capillary tube-like formation in vitro. J Immunol. 1992;148:3302–12.

36. Hase K, Kimura S, Takatsu H, Ohmae M, Kawano S, Kitamura H, Ito M, Watarai H, Hazelett CC, Yeaman C, Ohno H. M-Sec promotes membrane nanotube formation by interacting with Ral and the exocyst complex. Nat Cell Biol. 2009;11:1427–32.

37. Wolf FW, Sarma V, Seldin M, Drake S, Suchard SJ, Shao H, O'Shea KS, Dixit VM. B94, a primary response gene inducible by tumor necrosis factor-alpha, is expressed in developing hematopoietic tissues and the sperm acrosome. J Biol Chem. 1994;269:3633–40.

38. Jia L, Shi Y, Wen Y, Li W, Feng J, Chen C. The roles of TNFAIP2 in cancers and infectious diseases. 2018, 22:5188–5195.

39. Elgaaen BV, Olstad OK, Sandvik L, Odegaard E, Sauer T, Staff AC, Gautvik KM. ZNF385B and VEGFA are strongly differentially expressed in serous ovarian carcinomas and correlate with survival. PLoS One. 2012;7:e46317.

40. Xie CH, Cao YM, Huang Y, Shi QW, Guo JH, Fan ZW, Li JG, Chen BW, Wu BY. Long non-coding RNA TUG1 contributes to tumorigenesis of human osteosarcoma by sponging miR-9-5p and regulating POU2F1 expression. Tumour Biol. 2016;37:15031–41.

41. Qin S, Shi X, Wang C, Jin P, Ma F. Transcription Factor and miRNA Interplays Can Manifest the Survival of ccRCC Patients. Cancers (Basel) 2019, 11.

42. Zhao X, Dou J, Cao J, Wang Y, Gao Q, Zeng Q, Liu W, Liu B, Cui Z, Teng L, et al. Uncovering the potential differentially expressed miRNAs as diagnostic biomarkers for hepatocellular carcinoma based on machine learning in The Cancer Genome Atlas database. Oncol Rep. 2020;43:1771–84.

43. Zhang X, Lian Z, Padden C, Gerstein MB, Rozowsky J, Snyder M, Gingeras TR, Kapranov P, Weissman SM, Newburger PE. A myelopoiesis-associated regulatory intergenic noncoding RNA transcript within the human HOXA cluster. Blood. 2009;113:2526–34.

44. Lin M, Pedrosa E, Shah A, Hrabovsky A, Maqbool S, Zheng D, Lachman HM. RNA-Seq of human neurons derived from iPS cells reveals candidate long non-coding RNAs involved in neurogenesis and neuropsychiatric disorders. PLoS One. 2011;6:e23356.
45. Tian X, Ma J, Wang T, Tian J, Zhang Y, Mao L, Xu H, Wang S. Long Non-Coding RNA HOXA Transcript Antisense RNA Myeloid-Specific 1-HOXA1 Axis Downregulates the Immunosuppressive Activity of Myeloid-Derived Suppressor Cells in Lung Cancer. Front Immunol. 2018;9:473.

46. Li N, Zhan X. Identification of clinical trait-related lncRNA and mRNA biomarkers with weighted gene co-expression network analysis as useful tool for personalized medicine in ovarian cancer. 2019, 10:273–290.

47. Wan L, Kong J, Tang J, Wu Y, Xu E, Lai M, Zhang H. HOTAIRM1 as a potential biomarker for diagnosis of colorectal cancer functions the role in the tumour suppressor. J Cell Mol Med. 2016;20:2036–44.

48. Lu R, Zhao G, Yang Y, Jiang Z, Cai J, Zhang Z, Hu H. Long noncoding RNA HOTAIRM1 inhibits cell progression by regulating miR-17-5p/ PTEN axis in gastric cancer. 2019, 120:4952–4965.

**Figures**

![Figure 1](image.png)

**Figure 1**

The association between immune scores (A) and stromal scores (B) and overall survival with SARC patients.
Figure 2

(A-C) Heatmaps of DEGs, DEMs and DELs in the high vs. low immune scores groups. (D-F) Heatmaps of DEGs, DEMs and DELs in the high vs. low stromal scores groups. Green color represents high expression, and red represents low expression. (G-I) Venn diagrams showing the number of commonly regulated DEGs, DEMs and DELs in the immune and stromal scores groups.
Figure 3

The top 10 BP, MF, CC and pathway terms of the upregulated (A) and downregulated (B) DEGs.
Figure 4

The ceRNA network (A) and the PPI network (B). Red represents upregulation, and green represents downregulation. The circle nodes represent DEGs, the rectangle nodes represent DEMs, and the triangle nodes represent DELs.
Figure 5

Kaplan-Meier survival curves of APOL1, EFEMP1, LYZ, MEDAG, MYH11, RARRES1, TNFAIP2, TNFSF10, ZNF385A, hsa-miR-9-5p, hsa-miR-183-5p, CTD-2228K2.7, HOTAIRM1 and NCF1C that significantly associated with overall survival in SARCs patients.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- TableS4.xls
- TableS3.xls
- TableS2.xlsx
- TableS1.xlsx